Produkte & Lösungen
News & Events
Über uns

Fragment Based Drug Discovery: Case Histories and Experiences of Combining Orthogonal Methods

The number of approved drugs that are derived by Fragment Based Drug Discovery (FBDD) is on the rise. Three drugs are already on the market and more than thirty are in development.* FBDD is now an established key starting point for the discovery of high-quality preclinical candidates.

During the webinar, we will introduce the FBDD methodology, and discuss real cases from the pharmaceutical industry, focusing on the use of NMR together with other biophysical techniques. We will show the importance of using orthogonal approaches to improve the quality and the quantity of hits. Moreover we will discuss approaches to progress fragments when X-ray crystal structures are not available.

What to Expect

In this webinar Dr. Ben Davis, Vernalis Research, and Dr. Matteo Pennestri, Bruker Biospin, will discuss the application of Fragment Based Drug Discovery to drug discovery, and the integration of NMR with orthogonal methods for fragment screening and characterisation.

What You Will Learn

  • The crucial role of NMR as part of your FBDD tool box.
  • Real cases of FBS by NMR and the importance of using orthogonal methods
  • The use of NMR guided models to progress fragments when routine X-ray crystal structures are not available

Who Should Attend?

This webinar will be of interest to anyone interested in improving their lead discovery capabilities. This includes pharmaceutical companies, contract research organizations and academia, with and without previous experience in FBDD. Moreover any company which is part of this ecosystem, particularly fragment library vendors and computational chemistry software companies.


Dr. Matteo Pennestri

Product Manager, Pharmaceutical Business Unit, Bruker

Matteo Pennestri obtained his Ph.D. in Biophysical methods at the University of Tor Vergata Rome (collaboration with Merck Sharp and Dohme). Then he moved as NMR spectroscopist in the pharmaceutical industry (MSD and EISAI). After experiencing the pharma sector, he joined as application scientist Agilent Technologies first (ex. Varian) and Bruker afterwards. Recently he joined the Bruker Pharma unit as NMR specialist and product manager.

Dr. Ben Davis

Research Fellow, Vernalis R&D

Dr Ben Davis is an NMR spectroscopist and biophysicist by training. His research focus is applying FBLD methods to drug discovery programs involving challenging targets. Ben studied for his PhD in protein folding and ligand binding with Professor Alan Fersht at Cambridge University, and has over two decades experience studying molecular interactions between small molecules and biomolecules in drug discovery.